Tempus AI, Inc. - Class A Common Stock (TEM)
76.24
-3.19 (-4.02%)
NASDAQ · Last Trade: Nov 12th, 1:01 PM EST
News & Press Releases
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boommarketbeat.com
AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology
Via MarketBeat · November 11, 2026
Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting
Tempus AI, Inc. (NASDAQ: TEM) today announced that six abstracts (including three oral presentations) will be presented at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting taking place November 18–21 in Seoul. At this year’s meeting, Tempus will present clinical research on rare mesenchymal tumors, highlighting how advances in molecular diagnosis and classification are unlocking new treatment options.
By Tempus AI, Inc. · Via Business Wire · November 11, 2026
Can Cathie Wood's Ark Invest ETF Make a Comeback With Its Large SpaceX Position?fool.com
SpaceX will make the Ark Innovation ETF more volatile, and AI trends ultimately determine the fund's fate.
Via The Motley Fool · November 11, 2026
Tempus AI Surges on Earnings Beat, But Can the Rally Last?marketbeat.com
Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside.
Via MarketBeat · November 3, 2026
Tempus (TEM) Q3 2026 Earnings Call Transcriptfool.com
Oncology volume surged 32% while data licensing bookings topped $550 million year-to-date.
Via The Motley Fool · November 2, 2026
Tempus AI Revenue Up 23%; Gains Cut Net Loss: Rapid Earnings Reactionfool.com
Tempus AI raised its outlook on 23% revenue growth, but most of its smaller net loss came from paper gains on stock it holds, not the core business.
Via The Motley Fool · November 2, 2026
What Tempus AI (TEM) Said on Its Q3 Earnings Callmarketbeat.com
Tempus AI (NASDAQ:TEM) reported third-quarter 2026 revenue of $411.5 million, up 23% from a year earlier, as growth in oncology diagnostics and data-and-applications services continued to drive results. The company also raised its full-year revenue outlook and said it generated positive adjusted EBI
Via MarketBeat · November 2, 2026
Tempus Reports Third Quarter 2026 Results
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended September 30, 2026.
By Tempus AI, Inc. · Via Business Wire · November 2, 2026
Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling
Tempus AI, Inc. (NASDAQ: TEM) today announced that its xR assay has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device. The certification covers Tempus’ quality management system for "next-generation sequencing devices for cancer genomic profiling to support clinical management."
By Tempus AI, Inc. · Via Business Wire · October 26, 2026
Tempus Expands Strategic Collaboration with Bristol Myers Squibb
Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus’s largest licensors of de-identified oncology data.
By Tempus AI, Inc. · Via Business Wire · October 23, 2026
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions
Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, “BMS”) and Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) to build a specialized, curated dataset and agentic AI capabilities for Alzheimer’s disease and other neurological conditions. BMS also leads Pathos’s Series E financing and gains access to Pathos Foundry across its broader R&D portfolio.
By Pathos AI · Via Business Wire · October 23, 2026
Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC
Tempus AI, Inc. (NASDAQ: TEM) today announced results from a study evaluating an AI-enabled pre-screening panel for patients with advanced non-small cell lung cancer (NSCLC). The panel achieved greater than 80% sensitivity across all 12 biomarkers assessed, with sensitivity exceeding 90% for several biomarkers, supporting its potential to identify patients who may need confirmatory biomarker testing. Results from the study will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid.
By Tempus AI, Inc. · Via Business Wire · October 19, 2026
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winningmarketbeat.com
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.
Via MarketBeat · October 19, 2026
Tempus to Report Third Quarter 2026 Financial Results on November 2
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the third quarter ended September 30, 2026, before U.S. markets open on Monday, November 2, 2026.
By Tempus AI, Inc. · Via Business Wire · October 15, 2026
The $1 Trillion AI Healthcare Revolution: A New Era of Medical Innovation Is Taking Shape
AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034 New York, NY – October 15, 2026 – Artificial intelligence is starting to change the way healthcare works, and the opportunity is getting harder to ignore. From spotting diseases […]
Via FinancialNewsMedia · October 15, 2026
The $1 Trillion AI Healthcare Revolution: A New Era of Medical Innovation Is Taking Shape
AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034
By FN Media · Via GlobeNewswire · October 15, 2026
Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
Ambry Genetics, a leader in clinical genomic testing and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced the launch of GenomeNext™ and GenomeReveal™, a comprehensive whole genome sequencing (WGS) solution designed to help improve diagnosis of patients with rare diseases.
By Ambry Genetics · Via Business Wire · October 13, 2026
Tempus Announces Multi-Year Collaboration with Moderna and Merck
Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. The collaboration builds on joint efforts initiated last year and will support preparations for the potential commercialization of intismeran autogene.
By Tempus · Via Business Wire · October 7, 2026
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid.
By Tempus AI, Inc. · Via Business Wire · October 1, 2026
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated with undiagnosed moderate or severe mitral regurgitation (MR).
By Tempus AI, Inc. · Via Business Wire · September 28, 2026
Tempus AI Chief Accounting Officer Sells $529,650 of Stockfool.com
Sale follows 30% rebound in the stock year to date.
Via The Motley Fool · September 24, 2026
Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansionmarketbeat.com
Tempus AI (NASDAQ:TEM) Founder and CEO Eric Lefkofsky said the company’s second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business.
Speaking at Morgan Stanley’s Global Healthcare Conference, Lefkofsky said the diagnost
Via MarketBeat · September 21, 2026
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion’s RNA Foundation Model.
By Tempus AI, Inc. · Via Business Wire · September 21, 2026
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. The effort will create the first de-identified multimodal whole-genome sequencing (WGS) dataset built around disease populations and patient outcomes, specifically optimized for AI-driven research. Once this dataset is complete, Tempus plans to expand the effort with the goal of reaching one million genomes.
By Tempus AI, Inc. · Via Business Wire · September 11, 2026